Clinical Research
Emerging
Role of Gemcitabine in NSCLC (Medscape)
Summary, by Corey Langer, MD, of the World Conference on Lung Cancer
(September 2000) session focusing on gemcitabine and its use in the treatment
of NSCLC. Aimed at physicians. Registration required for free access to
Medscape. [9/00]
Use of
Gemcitabine in Non-Small Lung Cancer (Cancer Care Ontario
Practice Guideline Initiative)
Clinical practice guideline for the use of gemcitabine in non-small cell
lung cancer. Available as recommendations, structured abstract or full
text. Intended for physicians. [9/02]
Gemzar
(Lilly)
Manufacturer's website offers basic information about Gemzar.
Gemcitabine
(Gemzar) - Recent MEDLINE Abstracts (PubMed)
Gemcitabine
(Gemzar) - Clinical Trials (ClinicalTrials.gov)
Side Effects
Gemcitabine
(Gemzar) (CancerBACUP)
Factsheet describes gemcitabine (also known as Gemzar), how it is given
and some of its possible side effects. [11/02]
Gemzar
Therapy Side Effects (Eli Lilly)
Describes possible side effects that may be experienced with Gemzar
(gemcitabine) therapy.
Radiation
Recall Reaction Following Gemcitabine (PubMed)
Abstract from a case report in the August-September 2001 issue of Lung
Cancer describing a case of dermatitis and myositis in the upper
thorax after administration of gemcitabine. Thought to be a case of radiation
recall phenomenon, cessation of gemcitabine and and systemic steroids
are recommended for management and symptomatic relief. [9/01]
Gemcitabine (Gemzar) and Carboplatin (Paraplatin)
Gemcitabine
(Gemzar) and Carboplatin (Paraplatin) - Recent MEDLINE Abstracts
(PubMed)
Gemcitabine (Gemzar) and Vinorelbine
(Navelbine)
The
Novel and Effective Nonplatinum, Nontaxane Combination of Gemcitabine
and Vinorelbine in Advanced NSCLC (Cancer)
Reports on a Phase II study published in the July 2002 issue of
Cancer that evaluated the efficacy of gemcitabine and vinorelbine
in both untreated and previously treated patients with stage IIIB (with
pleural effusion) or stage IV NSCLC. Concluded that gemcitabine/vinorelbine
is an active, well-tolerated combination in both front-line and second/third
line therapy for stage IIIB/IV NSCLC. The response rate, median survival
rate, and one year survival compare favorably with platinum-based regimens.
The toxicity profile of the gemcitabine/vinorelbine combination is favorable
with minimal side effects aside from granulocytopenia. [5/02]
Gemcitabine
(Gemzar) and Vinorelbine (Navelbine) - Recent MEDLINE Abstracts
(PubMed)
Gemcitabine (Gemzar) and Alimta
(pemetrexed)
Phase
II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced
NSCLC (PubMed)
Study, published in the August 15, 2004 issue of Clinical Cancer
Research, that evaluated the efficacy and toxicity of pemetrexed
(Alimta) and gemcitabine (Gemzar) in patients with advanced NSCLC. Results
of the study indicated this combination had good tolerance and achieved
promising overall survival with extended one- and two-year survival rates.
Recommends further evaluation in randomized trials. [8/04]
Gemcitabine (Gemzar) for SCLC
Single-agent
Gemcitabine in Patients with Resistant SCLC (Annals
of Oncology)
Abstract of a study published in the April 2001 issue of the Annals
of Oncology to assess the activity and toxicity of gemcitabine in
patients with resistant SCLC. Concludes that gemcitabine has modest activity
in patients with resistant SCLC. [4/01]
|
